ClinicalThought™ HIV Faculty

  • Chris Beyrer, MD, MPH

    Associate Professor
    Director, Johns Hopkins Fogarty AIDS International Training and Research Program
    Founder and Director, Center for Public Health and Human Rights
    Johns Hopkins Bloomberg School of Public Health
    Baltimore, Maryland

    Chris Beyrer, MD, MPH, President, International AIDS Society, has no real or apparent conflicts of interest to report.
  • Richard E. Chaisson, MD

    Professor of Medicine, Epidemiology and International Health
    Johns Hopkins University
    Director, Johns Hopkins Center for AIDS Research and Center for Tuberculosis Research
    Baltimore, Maryland

    Richard E. Chaisson, MD, has disclosed that he has ownership interest in Merck.
  • Francesca Conradie, MBBCh

    Physician
    Faculty of Health Sciences
    University of Witwatersrand
    Johannesburg, South Africa

    Francesca Conradie, MBBCh, has disclosed that she has received funds for research support from Janssen and has served on advisory boards for Janssen and Sanofi-Aventis.
  • David A. Cooper, MD, DSc

    Director, Kirby Institute
    University of New South Wales
    Sydney, Australia

    David A. Cooper, MD, DSc, has disclosed that he has received consulting fees from Gilead Sciences, MSD, and ViiV and funds for research support from AbbVie and MSD.
  • Eric S. Daar, MD

    Chief, Division of HIV Medicine
    Harbor-UCLA Medical Center
    Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Eric S. Daar, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Teva, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.
  • Joseph J. Eron, Jr., MD

    Professor of Medicine and Epidemiology
    University of North Carolina School of Medicine
    Director, AIDS Clinical Trials Unit
    University of North Carolina
    Chapel Hill, North Carolina

    Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Merck, Tibotec/Janssen, and Tobira; has served on data and safety monitoring boards for Vertex; and has received funds for research support from AbbVie and GlaxoSmithKline/ViiV.
  • Joel E. Gallant, MD, MPH

    Medical Director of Specialty Services
    Southwest CARE Center
    Santa Fe, New Mexico
    Adjunct Professor of Medicine
    Division of Infectious Diseases
    Johns Hopkins University School of Medicine
    Baltimore, Maryland

    Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Theratechnologies, and ViiV and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sangamo, and ViiV.
  • Giovanni Guaraldi, MD

    University Investigator
    Infectious and Tropical Diseases Clinic
    Department of Medicine and Medical Specialties for Children and Adults
    University of Modena and Reggio Emilia
    Modena, Italy

    Giovanni Guaraldi, MD, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Bristol-Myers Squibb, Gilead Sciences, and Merck.
  • W. David Hardy, MD

    Clinical Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    W. David Hardy, MD, has disclosed that he has served as a consultant for Boehringer Ingelheim, Calimmune, Gilead Sciences, Janssen, and ViiV; has received research support from Gilead Sciences, Janssen, Vertex, and ViiV; and has ownership interest in Merck.
  • Charles B. Hicks, MD

    Professor of Clinical Medicine
    Director,
     Owen Clinic
    University of California, San Diego
    San Diego, California

    Charles B. Hicks, MD, has disclosed that he has received consulting fees from Janssen, Merck, and ViiV and royalties from UpToDate, Inc.
  • Lisa Hightow-Weidman, MD, MPH

    Associate Professor
    Division of Infectious Diseases
    Department of Medicine
    University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina

    Lisa Hightow-Weidman, MD, MPH, has no real or apparent conflicts of interest to report.
  • Quarraisha Abdool Karim, PhD

    Associate Scientific Director
    CAPRISA
    Principal Investigator, CAPRISA Clinical Trials Unit
    Durban, South Africa
    Professor in Clinical Epidemiology
    Columbia University
    New York, New York
    Honorary Professor in Public Health
    University of KwaZulu-Natal
    Durban, South Africa

    Quarraisha Abdool Karim, PhD, has disclosed that she has intellectual property rights/patents from Gilead Sciences.

  • Daniel R. Kuritzkes, MD

    Chief, Division of Infectious Diseases
    Brigham and Women's Hospital
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV and funds for research support from Abbott, Gilead Sciences, and Merck.

  • Josep M. Llibre, MD

    HIV Unit and “Lluita contra la SIDA Foundation”
    Hospital Universitari Germans Trias I Pujol
    Badalona
    Universitat Autònoma de Barcelona
    Barcelona, Spain

    Josep M. Llibre, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, and ViiV.
  • Jeanne Marrazzo, MD, MPH

    Professor of Medicine
    Division of Infectious Diseases
    University of Washington
    Medical Director
    Seattle STD/HIV Prevention Training Center
    Seattle, Washington

    Jeanne Marrazzo, MD, MPH, has disclosed that she has received funds for research support from Cepheid, Medicis, and MethylGene.
  • Karam Mounzer, MD

    Clinical Associate Professor of Medicine
    Department of Internal Medicine and Infectious Disease
    University of Pennsylvania
    Medical Director
    Philadelphia FIGHT
    Philadelphia, Pennsylvania

    Karam Mounzer, MD, has disclosed that he has received consulting fees from Abbott, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, and ViiV; fees for non-CME/CE services from Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, and Merck; and funds for research support from Gilead Sciences, Johnson & Johnson, Merck, and ViiV.
  • Kevin M. O'Hara, MMSc, MS, PA-C

    Assistant Professor of Medicine
    Physician Associate Program
    Yale School of Mediciine
    New Haven, Connecticut

    Kevin M. O’Hara, MMSc, MS, PA-C, has disclosed that he has ownership interest in AbbVie and Gilead Sciences.
  • William G. Powderly, MD

    J. William Campbell Professor of Medicine
    Co-Director, Division of Infectious Diseases
    Washington University School of Medicine
    St Louis, Missouri

    William G. Powderly, MD, has disclosed that he has received consulting fees from Merck and has served on data and safety monitoring boards for Calimmune and Tibotec/Janssen.
  • Anton L. Pozniak, MD, FRCP

    Consultant Physician
    Director of HIV Services

    Department of HIV and Genitourinary Medicine
    Chelsea and Westminster Hospital NHS Foundation Trust
    London, United Kingdom

    Anton L. Pozniak, MD, FRCP, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, Merck, and ViiV.
  • Jürgen K. Rockstroh, MD

    Professor of Medicine
    University of Bonn
    Bonn, Germany

    Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abbott, AbbVie, Bionor, Bristol-Myers Squibb, Cipla, Gilead Sciences, Janssen, Merck, and ViiV.
  • Paul E. Sax, MD

    Clinical Director
    HIV Program and Division of Infectious Diseases
    Brigham and Women's Hospital
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Paul E. Sax, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and funds for research support from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline/ViiV.
  • Renslow Sherer, MD

    Director, International HIV Training Center
    Professor of Medicine
    University of Chicago
    Chicago, Illinois

    Renslow Sherer, MD, has no real or apparent conflicts of interest to report.
  • Kimberly Y. Smith, MD, MPH

    Associate Professor of Medicine
    Division of Infectious Diseases
    Rush University Medical Center
    Chicago, Illinois

    Kimberly Y. Smith, MD, MPH, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV.
  • Kathleen E. Squires, MD

    W. Paul and Ida H. Havens Professor of Infectious Diseases
    Director,
    Division of Infectious Diseases
    Sidney Kimmel Medical College of Thomas Jefferson University
    Philadelphia, Pennsylvania

    Kathleen E. Squires, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences.
  • Donna E. Sweet, MD, MACP, AAHIVS

    Professor, Department of Medicine
    Director, Internal Medicine Education
    Via Christi Regional Medical Center-St Francis Campus
    University of Kansas School of Medicine
    Wichita, Kansas

    Donna E. Sweet, MD, has disclosed that she has received fees for non-CME services from Abbott, Boehringer Ingelheim, Bristol Myers-Squibb, Gilead Sciences, Pfizer, and Tibotec/Janssen and grants for clinical research from Pfizer.
  • Babafemi Taiwo, MBBS

    Associate Professor
    Division of Infectious Diseases
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees and funds for research support from ViiV.
  • Mark A. Wainberg, PhD

    Director, McGill AIDS Centre
    McGill University
    Montreal, Quebec, Canada

    Mark A. Wainberg, PhD, has disclosed that he has received consulting fees from Janssen and Merck.
  • David A. Wohl, MD

    Professor of Medicine
    School of Medicine
    Site Leader,  AIDS Clinical Trials Unit-Chapel Hill
    University of North Carolina at Chapel Hill
    Director, North Carolina AIDS Training and Education Center
    Chapel Hill, North Carolina
    Co-Director, HIV Services
    North Carolina Department of Correction
    Raleigh, North Carolina

    David A. Wohl, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, and ViiV and funds for research support from Gilead Sciences.
  • Andrew R. Zolopa, MD

    Professor of Medicine
    Director
    , Stanford Positive Care Program
    Principal Investigator, Stanford AIDS Clinical Trials Unit
    Stanford University School of Medicine
    Stanford, California

    Andrew R. Zolopa, MD, has disclosed that he has served as a consultant for Gilead Sciences and Janssen and received funds for research support from Gilead Sciences, Janssen, Pfizer, and ViiV.